January 30, 2007

Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0 10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

67

January 30, 2007

10/803,344

March 17, 2004

514/394   514/339 546/210 548/309.7

A61K   31/415   (20060101)   A61K   31/44   (20060101)   C07D   401/02   (20060101)   C07D   403/02   (20060101)  

RELATED APPLICATION This application claims the benefit of U.S. Provisional Application No. 60/455,437, filed Mar. 17, 2003 and U.S. Provisional Application No. 60/531,203, filed Dec. 19, 2003, each of which are incorporated herein by reference.

514/394   514/339   546/210   548/309.7  

	7507552 - Crystallization of histone deacetylase 2 - Owned by Takeda San Diego, Inc. (San Diego, CA) Provided are crystals relating to histone deacetylase 2 (HDAC-2) and its various uses.
	7381825 - Histone deacetylase inhibitors - Owned by Takeda San Diego, Inc. (San Diego, CA) Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.
	7375228 - Histone deacetylase inhibitors - Owned by Takeda San Diego, Inc. (San Diego, CA) Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.